Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Q-linea ABCHIX:QLINES 66 Cash-to-Debt is 16.00 as of Jun. 2026, which is 67% below its 10-year median of 49.05. GuruFocus rates CHIX:QLINES with a GF Score™ of 66/100 and a GF Value™ of kr1,639.51. The stock has 3 warning signs investors should review. Among 842 Medical Devices & Instruments companies, Q-linea AB ranks better than 78.98% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Q-linea AB's cash to debt ratio for the quarter that ended in Jun. 2026 was 16.00.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Q-linea ABcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Q-linea AB's Cash-to-Debt or its related term are showing as below:
CHIX:QLINEs'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08 Med: 49.05 Max: No Debt
Current: 16
During the past 11 years, Q-linea AB's highest Cash to Debt Ratio was No Debt. The lowest was 0.08. And the median was 49.05.
CHIX:QLINEs's Cash-to-Debt is ranked better than 78.98% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 1.635
vs CHIX:QLINEs: 16.00
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Q-linea AB Cash-to-Debt Related Terms
Q-linea AB Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Q-linea AB's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CHIX:QLINES vs ABT, SYK, MDT: Cash-to-Debt Comparison
For the Medical Devices subindustry, Q-linea AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-linea AB Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-linea AB's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Q-linea AB's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-linea AB (CHIX:QLINES) has a Cash-to-Debt of 16.00 as of Jun. 2026. This is 67% below median its historical median of 49.05. Over the past decade, Q-linea AB's Cash-to-Debt has ranged from 0.08 to 10,000.00. According to the industry distribution chart, Q-linea AB ranks #177 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 21%.
Is Q-linea AB's Cash-to-Debt too high?
Q-linea AB's current Cash-to-Debt of 16.00 is 67% below median its 10-year median of 49.05. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 10,000.00. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. Q-linea AB's value of 16.00 is 878.6% above this industry median. Based on the distribution chart, Q-linea AB ranks #177 out of 842 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Q-linea AB has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's Cash-to-Debt compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-linea AB ranks #177 out of 842 companies for Cash-to-Debt. This places Q-linea AB in the top 21% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 1.64. Q-linea AB's value of 16.00 is 878.6% above this benchmark. Historically, Q-linea AB's own Cash-to-Debt has ranged from 0.08 to 10,000.00 over the past decade. While the company's 10-year median is 49.05 vs. the industry median of 1.64, Q-linea AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-linea AB's current Cash-to-Debt of 16.00 is 878.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-linea AB's current Cash-to-Debt is 16.00, which is 67% below median its own 10-year median of 49.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Q-linea AB (CHIX:QLINES) has a current Cash-to-Debt of 16.00. The stock's GF Value™ is kr1,639.51, compared to a current price of kr1,610.00 — trading 1.8% below its estimated fair value. The current Cash-to-Debt is 16.00, which is 67% below median its 10-year median of 49.05 and 878.6% above the Medical Devices & Instruments industry median of 1.64. Q-linea AB's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Q-linea AB (CHIX:QLINES), the current Cash-to-Debt is 16.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Q-linea AB (CHIX:QLINES) Overvalued in 2026?
Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued.
The current stock price of kr1,610.00 is trading 1.8% below its estimated GF Value™ of kr1,639.51.
Key valuation signals for CHIX:QLINES:
Cash-to-Debt: 16.00 (67% below median its 10-year median of 49.05)
GF Value™: kr1,639.51 vs. price of kr1,610.00 (1.8% below fair value)
Industry Position: 878.6% above the Medical Devices & Instruments median (#177 of 842)
No single metric tells the full story. See the CHIX:QLINES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
66GF Score
Get the complete analysis for CHIX:QLINES
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:QLINES has been successfully added to your 
